The U.S. FDA granted accelerated approval to GSK and Nuvalent's kinase inhibitor neladalkib (Nelkarmi) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer previously treated with ALK TKIs and chemotherapy. Approval was based on the ALKOVE-1 trial, which showed overall response rates up to 49%. Prescribing guidelines mandate a 150 mg daily dose alongside warnings for hepatotoxicity and renal toxicity. GSK expects Nelkarmi to exceed sales of its drug Jideytro.
FDA Approval and eligibility criteria
- ▪The U.S. FDA granted accelerated approval on November 17, 2026 to neladalkib (Nelkarmi) for adult patients with locally advanced or metastatic ALK-positive non-small cell lung cancer who had previously received treatment
- ▪To qualify for neladalkib treatment, patients must have received prior treatment with either one ALK tyrosine kinase inhibitor consisting of alectinib, or two or more prior ALK TKIs alongside platinum-based chemotherapy
Efficacy results in ALKOVE-1 trial
- ▪In the ALKOVE-1 trial cohort of 155 patients who received two or more prior ALK TKIs with platinum-based chemotherapy, neladalkib achieved an overall response rate of 32%
- ▪In the open-label ALKOVE-1 trial, neladalkib demonstrated an overall response rate of 49% among 67 patients who had received one prior ALK TKI consisting of alectinib in the metastatic setting
- ▪For responding patients in the heavily pretreated ALKOVE-1 trial cohort, duration of response to neladalkib reached six months or longer for 69% and twelve months or longer for 51%
- ▪Among responding patients in the ALKOVE-1 trial who received one prior treatment, 76% maintained a response duration of six months or longer, and 52% maintained a response for twelve months or longer
Safety warnings and adverse reactions
- ▪Adverse reactions occurring in at least 20% of patients treated with neladalkib included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue
- ▪The official FDA prescribing information for neladalkib includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity
GSK commercial strategy and expectations
- ▪GSK received FDA authorization for neladalkib to expand its therapeutic franchise in lung cancer, which represents the leading cause of cancer death
- ▪GSK reported commercial expectations that Nelkarmi will represent a larger sales opportunity than GSK's existing drug Jideytro
Story comments
Loading comments…